Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

WHO: Merck & Co Phase III success a ‘turning point’ for Ebola vaccine

The WHO says early results from Merck & Co’s Phase III Ebola vaccine trial show it is “highly effective” against Ebola and a “turning-point” in R&D.

The WHO's Marie-Paule Kieney

Amgen prepped to compete in US filgastrim market post Sandoz's Zarxio launch

Neupogen to bring in substantial future sales despite the arrival of Sandoz's biosimilar Zarxio in September, says Amgen.

US firm offers CRISPR viral knock-out library for R&D

Genomics services company Cellecta is offering gene-editing tool CRISPR to researchers wanting to “knock out” human gene functions.

Merck & Co. 'continues to augment' biologics pipeline with $605m cCAM deal

Merck & Co. has strengthened its biologics pipeline through the acquisition of mAb developer cCAM and an extension of its nanobody deal with Ablynx.

Novartis launches UK biopharma spin-out Mereo

Novartis has spun out three of its mid-to late-stage biologic candidates into a $119m (€108m) biotech.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...

On demand Supplier Webinars

The BioPharmaReporter Fermentation & Science Technology Forum
William Reed Business Media
All supplier webinars